{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:39:33Z","timestamp":1793900373497,"version":"4.8.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.seizure.2014.06.004","type":"journal-article","created":{"date-parts":[[2014,6,12]],"date-time":"2014-06-12T06:03:39Z","timestamp":1402553019000},"page":"685-691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Behavioral side-effects of levetiracetam in children with epilepsy: A systematic review"],"prefix":"10.1016","volume":"23","author":[{"given":"Elisabeth","family":"Halma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton J.A.","family":"de Louw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Klinkenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert P.","family":"Aldenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique M.","family":"IJff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Majoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.seizure.2014.06.004_bib0005","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1177\/08830738020170010201","article-title":"Update on the epidemiology and prognosis of pediatric epilepsy","volume":"17","author":"Shinnar","year":"2002","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2014.06.004_bib0010","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1469-8749.2007.00487.x","article-title":"Behavior and social competency in idiopathic and cryptogenic childhood epilepsy","volume":"49","author":"Berg","year":"2007","journal-title":"Dev Med Child Neurol"},{"issue":"Suppl. 1","key":"10.1016\/j.seizure.2014.06.004_bib0015","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1177\/088307380401900104","article-title":"Behavioral and psychiatric adverse events associated with antiepileptic drugs commonly used in pediatric patients","volume":"19","author":"Glauser","year":"2004","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2014.06.004_bib0020","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/JCP.0b013e318253a186","article-title":"Behavioral adverse effects of antiepileptic drugs in epilepsy","volume":"32","author":"Eddy","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.seizure.2014.06.004_bib0025","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.seizure.2014.06.004_bib0030","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejphar.2006.02.022","article-title":"Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein","volume":"536","author":"Gillard","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.seizure.2014.06.004_bib0035","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1046\/j.1528-1157.2001.41300.x","article-title":"Pharmacokinetic study of levetiracetam in children","volume":"42","author":"Pellock","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2014.06.004_bib0040","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1528-1167.2007.01090.x","article-title":"Pharmacokinetics of levetiracetam in infants and young children with epilepsy","volume":"48","author":"Glauser","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2014.06.004_bib0045","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1212\/01.wnl.0000297512.18364.40","article-title":"Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures","volume":"70","author":"Noachtar","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2014.06.004_bib0050","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","article-title":"Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy","volume":"69","author":"Berkovic","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2014.06.004_bib0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1528-1167.2011.03300.x","article-title":"Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study","volume":"53","author":"Delanty","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2014.06.004_bib0060","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1528-1167.2006.00372.x","article-title":"Efficacy and safety of levetiracetam (up to 2000mg\/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study","volume":"47","author":"Tsai","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2014.06.004_bib0065","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1528-1167.2008.01817.x","article-title":"Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial","volume":"50","author":"Peltola","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2014.06.004_bib0070","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1528-1167.2008.01729.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures","volume":"50","author":"Wu","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2014.06.004_bib0075","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000197109","article-title":"Efficacy and safety of levetiracetam (3,000mg\/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures","volume":"61","author":"Xiao","year":"2009","journal-title":"Eur Neurol"},{"key":"10.1016\/j.seizure.2014.06.004_bib0080","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000mg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2014.06.004_bib0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/seiz.2000.0380","article-title":"A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000mg daily and 4000mg daily, without titration in patients with refractory epilepsy","volume":"9","author":"Betts","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2014.06.004_bib0090","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2014.06.004_bib0095","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2014.06.004_bib0100","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1528-1167.2008.01981.x","article-title":"Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures","volume":"50","author":"Pina-Garza","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2014.06.004_bib0105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ejpn.2007.09.004","article-title":"Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study","volume":"12","author":"Callenbach","year":"2008","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.seizure.2014.06.004_bib0110","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.seizure.2005.02.004","article-title":"Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy","volume":"14","author":"Grosso","year":"2005","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2014.06.004_bib0115","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1046\/j.1528-1157.2002.13101.x","article-title":"Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial","volume":"43","author":"Glauser","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2014.06.004_bib0120","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.seizure.2007.02.004","article-title":"Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy","volume":"16","author":"Grosso","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2014.06.004_bib0125","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1059-1311(03)00193-6","article-title":"Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience","volume":"13","author":"Tan","year":"2004","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2014.06.004_bib0130","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/j.1528-1167.2009.02197.x","article-title":"Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial","volume":"50","author":"Levisohn","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2014.06.004_bib0135","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/01.wnl.0000217916.00225.3a","article-title":"Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures","volume":"66","author":"Glauser","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2014.06.004_bib0140","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1528-1167.2010.02976.x","article-title":"A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy","volume":"52","author":"Fattore","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2014.06.004_bib0145","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.seizure.2004.10.004","article-title":"Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial","volume":"14","author":"Lagae","year":"2005","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2014.06.004_bib0150","first-page":"CD001901","article-title":"Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review","volume":"9","author":"Mbizvo","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.seizure.2014.06.004_bib0155","first-page":"S53","article-title":"Post RM,Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders","volume":"53","author":"Ketter","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2014.06.004_bib0160","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.yebeh.2005.01.005","article-title":"Ketter's hypothesis of the mood effects of antiepileptic drugs coupled to the mechanism of action of topiramate and levetiracetam","volume":"6","author":"Roberts","year":"2005","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2014.06.004_bib0165","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1212\/01.WNL.0000091865.46063.67","article-title":"Discontinuation of levetiracetam because of behavioral side effects: a case-control study","volume":"61","author":"White","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2014.06.004_bib0170","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"10.1016\/j.seizure.2014.06.004_bib0175","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/0883073811417183","article-title":"A long-term open-label extension study assessing cognition and behavior, tolerability, safety, and efficacy of adjunctive levetiracetam in children aged 4 to 16 years with partial-onset seizures","volume":"27","author":"Schiemann-Delgado","year":"2012","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2014.06.004_bib0180","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1090-3798(03)00041-2","article-title":"Effect of levetiracetam in refractory childhood epilepsy syndromes","volume":"7","author":"Lagae","year":"2003","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.seizure.2014.06.004_bib0185","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1059131102001723","article-title":"A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy","volume":"12","author":"Nakken","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2014.06.004_bib0190","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1111\/j.1528-1167.2005.00337.x","article-title":"Levetiracetam efficacy in epileptic syndromes with continuous spikes and waves during slow sleep: experience in 12 cases","volume":"46","author":"Aeby","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2014.06.004_bib0195","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pediatrneurol.2006.09.018","article-title":"Levetiracetam monotherapy in children with epilepsy","volume":"36","author":"Khurana","year":"2007","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2014.06.004_bib0200","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/0883073807309784","article-title":"Levetiracetam versus carbamazepine monotherapy for partial epilepsy in children less than 16 years of age","volume":"23","author":"Perry","year":"2008","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2014.06.004_bib0205","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1469-8749.2008.03099.x","article-title":"Levetiracetam in absence epilepsy","volume":"50","author":"Verrotti","year":"2008","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.seizure.2014.06.004_bib0210","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.clinthera.2010.09.017","article-title":"Adjunctive levetiracetam in patients aged 1 month to <4 years with partial-onset seizures: subpopulation analysis of a prospective, open-label extension study of up to 48 weeks","volume":"32","author":"Pina-Garza","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.seizure.2014.06.004_bib0215","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.seizure.2010.12.017","article-title":"A prospective open-labeled trial with levetiracetam in pediatric epilepsy syndromes: continuous spikes and waves during sleep is definitely a target","volume":"20","author":"Chhun","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2014.06.004_bib0220","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.seizure.2012.10.003","article-title":"Effects of levetiracetam on seizure frequency and neuropsychological impairments in children with refractory epilepsy with secondary bilateral synchrony","volume":"22","author":"Kanemura","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2014.06.004_bib0225","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00431-013-2125-1","article-title":"Initial anticonvulsant monotherapy in routine care of children and adolescents: levetiracetam fails more frequently than valproate and oxcarbazepine due to a lack of effectiveness","volume":"173","author":"Bertsche","year":"2014","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.seizure.2014.06.004_bib0230","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.seizure.2008.11.006","article-title":"The impact of side effects on long-term retention in three new antiepileptic drugs","volume":"18","author":"Bootsma","year":"2009","journal-title":"Seizure"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105913111400168X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105913111400168X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:44:43Z","timestamp":1761011083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105913111400168X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S105913111400168X"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2014.06.004","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Behavioral side-effects of levetiracetam in children with epilepsy: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2014.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}